After Aspen Pharmacare Holdings Ltd admitted that it was a party to an illegal, anti-competitive agreement and paid the UK National Health Service (NHS) £8m following an investigation by the Competition and Markets Authority (CMA), the British Generic Manufacturers Association (BGMA) has reacted to the CMA’s investigation by condemning anti-competitive behavior.
Aspen’s settlement resulted from an investigation by the CMA into anti-competitive arrangements involving the supply of fludrocortisone 0.1mg tablets. (Also...